Tango Therapeutics Q2 revenue drops, net loss widens
Overview
Tango Q2 2025 collaboration revenue declines compared to same period last year
Company reports net loss of $38.9 mln, EPS of $0.35 for Q2 2025
Tango advancing TNG462 and TNG456 trials, data expected later this year
Outlook
Company expects TNG462 clinical data update in 2H 2025
Tango anticipates cash reserves to fund operations into Q1 2027
Company plans registrational trial for TNG462 in pancreatic cancer next year
Tango expects TNG260 clinical data presentation in 2H 2025
Result Drivers
COST MANAGEMENT - Reduced R&D expenses due to decreased spending on discontinued programs, offset by increased investment in TNG462, TNG456, and TNG961
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Collaboration Revenue |
| $3.18 mln |
|
Q2 EPS |
| -$0.35 |
|
Q2 Net Income |
| -$38.85 mln |
|
Q2 Basic EPS |
| -$0.35 |
|
Q2 Operating Expenses |
| $44.15 mln |
|
Q2 Operating Income |
| -$40.97 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Tango Therapeutics Inc is $9.50, about 30.6% above its August 4 closing price of $6.59
Press Release: ID:nGNX6cXXtr
